Loading stock data…
$11.59+0.01 (+0.09%)
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally.
Amarin Corporation plc in the Healthcare sector is trading at $11.59 with a market capitalization of $304M. Wall Street consensus targets $12.50 (2 analysts), implying a +7.9% move over the next 12 months. The stock is currently near its 52-week low of $11.34, remaining 19.9% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 7 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $42.21M↓ | $45.13M↓ | $49.22M↓ | $49.67M↓ | $72.74M |
| Gross Profit | $14.99M↓ | $17.77M↓ | $23.17M↑ | $22.21M↓ | $50.36M |
| Operating Income | -$11.97M↓ | -$8.01M↓ | -$2.26M↓ | -$1.70M↓ | $6.77M |
| Net Income | -$7.65M↑ | -$10.51M↓ | -$1.22M↑ | -$7.74M↑ | -$14.14M |
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only ...